|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0036525,
umls-concept:C0205179,
umls-concept:C0205390,
umls-concept:C0389883,
umls-concept:C0666551,
umls-concept:C1513884,
umls-concept:C1517927,
umls-concept:C1521808,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C2603343
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-7-12
|
|
pubmed:abstractText |
Because treatment of metastatic colon cancer is noncurative, new treatments are needed. This trial evaluated the antitumor effects of two targeted anticancer agents: (a) ISIS 3521, an antisense inhibitor of the protein kinase C alpha; and (b) ISIS 5132, an antisense inhibitor of c-raf kinase in patients untreated previously with recurrent or metastatic colorectal carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/ISIS 3521,
http://linkedlifedata.com/resource/pubmed/chemical/ISIS 5132,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Oligodeoxyribonucleotides, Antisense,
http://linkedlifedata.com/resource/pubmed/chemical/PRKCA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase C,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase C-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-raf,
http://linkedlifedata.com/resource/pubmed/chemical/Thionucleotides
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2188-92
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12114419-Adenocarcinoma,
pubmed-meshheading:12114419-Adult,
pubmed-meshheading:12114419-Aged,
pubmed-meshheading:12114419-Antineoplastic Agents,
pubmed-meshheading:12114419-Colorectal Neoplasms,
pubmed-meshheading:12114419-Dose-Response Relationship, Drug,
pubmed-meshheading:12114419-Enzyme Inhibitors,
pubmed-meshheading:12114419-Female,
pubmed-meshheading:12114419-Humans,
pubmed-meshheading:12114419-Infusions, Intravenous,
pubmed-meshheading:12114419-Isoenzymes,
pubmed-meshheading:12114419-Male,
pubmed-meshheading:12114419-Maximum Tolerated Dose,
pubmed-meshheading:12114419-Middle Aged,
pubmed-meshheading:12114419-Oligodeoxyribonucleotides, Antisense,
pubmed-meshheading:12114419-Protein Kinase C,
pubmed-meshheading:12114419-Protein Kinase C-alpha,
pubmed-meshheading:12114419-Proto-Oncogene Proteins c-raf,
pubmed-meshheading:12114419-Thionucleotides,
pubmed-meshheading:12114419-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
|
|
pubmed:affiliation |
Ottawa Regional Cancer Centre, Ottawa, Ontario, K1H 8L6 Canada. Christine.Cripps@orcc.on.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
